Ethicon has agreed to buy Takeda’s TachoSil Fibrin Sealant Patch, a ready-to-use surgical patch developed to help surgeons to achieve fast and reliable bleeding control and tissue sealing, for $400m. Ethicon will purchase the assets and licenses required to manufacture, license, and commercialise TachoSil, which is marketed in more than 50 countries around the world, and Takeda will continue to manage its ownership of manufacturing facility in Austria, produce TachoSil products, and supply them to Ethicon.
“Ethicon acquires Takeda’s TachoSil“
Christophe Weber, Takeda president and CEO, said: “These initial divestitures represent important steps in advancing the growth strategy Takeda outlined following our transformational acquisition of Shire earlier this year. We are working to strategically simplify and optimize our portfolio, while also rapidly deleveraging and continuing to invest in our growth drivers as a global, values-based, R&D-driven biopharmaceutical leader.”